CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: BRSS; CDMT; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); Deubiquitinating enzyme CYLD; EAC; MFT; MFT1; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; SBS; TEM; Ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; Ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; Ubiquitin-specific-processing protease CYLD; USPL2
Gene Aliases: 2010013M14Rik; 2900009M21Rik; BOS_17130; BRSS; C130039D01Rik; CDMT; CYLD; CYLD1; CYLDI; EAC; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; Rp1; Rp1h; SBS; TEM; USPL2